Best Biotech Stocks To Consider - July 29th

Key Points

• MarketBeat's Top Picks: Thermo Fisher Scientific, AbbVie, Danaher, Veeva Systems, and IQVIA are highlighted as the top biotech stocks to consider this month.
• Volatility Factors: Biotech stocks often face significant price fluctuations due to lengthy clinical trials, regulatory hurdles, and substantial R&D expenses, making factors like clinical trial results and partnerships crucial for investor evaluation.
• Stock Performance: Notable performance stats include Thermo Fisher's market cap at $183.05 billion and a 52-week stock price range of $385.46 to $627.88.

Thermo Fisher Scientific, AbbVie, Danaher, Veeva Systems, and IQVIA are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies whose core business involves researching, developing, and commercializing products based on biological processes—such as new drugs, gene therapies, diagnostics, and agricultural biotech solutions. Because these companies often face lengthy clinical trials, strict regulatory approvals, and heavy R&D expenditures, their stock prices can be highly volatile. Investors in biotech equities typically evaluate factors like clinical trial results, patent portfolios, and strategic partnerships to gauge a company’s growth potential. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of TMO stock traded down $0.04 during trading on Tuesday, hitting $484.92. The company had a trading volume of 1,296,043 shares, compared to its average volume of 2,509,699. The stock's 50-day moving average is $415.18 and its two-hundred day moving average is $468.77. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $183.05 billion, a price-to-earnings ratio of 28.04, a price-to-earnings-growth ratio of 2.56 and a beta of 0.77. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $627.88.

Read Our Latest Research Report on TMO

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of ABBV traded up $3.40 during trading hours on Tuesday, hitting $191.92. The company had a trading volume of 2,865,193 shares, compared to its average volume of 6,829,496. The stock's 50 day moving average price is $187.68 and its 200 day moving average price is $189.94. AbbVie has a 52-week low of $163.81 and a 52-week high of $218.66. The firm has a market cap of $339.01 billion, a P/E ratio of 81.85, a P/E/G ratio of 1.25 and a beta of 0.48. The company has a quick ratio of 0.64, a current ratio of 0.76 and a debt-to-equity ratio of 44.14.

Read Our Latest Research Report on ABBV

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Shares of NYSE:DHR traded up $2.75 during midday trading on Tuesday, reaching $205.69. The company's stock had a trading volume of 2,175,152 shares, compared to its average volume of 4,263,302. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The firm has a 50 day moving average of $196.51 and a 200-day moving average of $203.22. Danaher has a 12-month low of $171.00 and a 12-month high of $281.70. The firm has a market capitalization of $147.28 billion, a P/E ratio of 43.76, a PEG ratio of 2.86 and a beta of 0.77.

Read Our Latest Research Report on DHR

Veeva Systems (VEEV)

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.

NYSE VEEV traded down $4.86 during trading hours on Tuesday, hitting $287.73. The company's stock had a trading volume of 715,731 shares, compared to its average volume of 1,326,247. The company has a market cap of $47.02 billion, a P/E ratio of 60.81, a price-to-earnings-growth ratio of 2.30 and a beta of 0.98. The company's 50 day simple moving average is $276.11 and its two-hundred day simple moving average is $245.18. Veeva Systems has a 12 month low of $177.41 and a 12 month high of $296.72.

Read Our Latest Research Report on VEEV

IQVIA (IQV)

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

NYSE IQV traded down $3.82 on Tuesday, hitting $193.94. 983,313 shares of the company traded hands, compared to its average volume of 2,035,440. The company has a market capitalization of $32.97 billion, a price-to-earnings ratio of 28.03, a P/E/G ratio of 2.18 and a beta of 1.30. IQVIA has a 52-week low of $134.65 and a 52-week high of $252.88. The business's 50 day moving average price is $158.18 and its 200-day moving average price is $169.99. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45.

Read Our Latest Research Report on IQV

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.